Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 273

1.

Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.

Mattsson N, Tosun D, Insel PS, Simonson A, Jack CR Jr, Beckett LA, Donohue M, Jagust W, Schuff N, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2014 May;137(Pt 5):1550-61. doi: 10.1093/brain/awu043. Epub 2014 Mar 12.

2.

Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.

Yew B, Nation DA; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2017 Jul 1;140(7):1987-2001. doi: 10.1093/brain/awx112.

PMID:
28575149
3.

Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.

Lin KJ, Hsiao IT, Hsu JL, Huang CC, Huang KL, Hsieh CJ, Wey SP, Yen TC.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1304-14. doi: 10.1007/s00259-016-3359-8. Epub 2016 Mar 22.

PMID:
27003417
4.

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA; 18F-AV-1451-A05 investigators.

Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.

5.

Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.

Tosun D, Schuff N, Jagust W, Weiner MW; Alzheimer''s Disease Neuroimaging Initiative.

Neurodegener Dis. 2016;16(1-2):87-94. doi: 10.1159/000439257. Epub 2015 Nov 12.

PMID:
26560336
6.

Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.

Tateno A, Sakayori T, Kawashima Y, Higuchi M, Suhara T, Mizumura S, Mintun MA, Skovronsky DM, Honjo K, Ishihara K, Kumita S, Suzuki H, Okubo Y.

Int J Geriatr Psychiatry. 2015 May;30(5):505-13. doi: 10.1002/gps.4173. Epub 2014 Jul 7.

PMID:
25043833
7.

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.

Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner MW; Alzheimer's Disease Neuroimaging Initiative*.

Brain. 2015 Mar;138(Pt 3):772-83. doi: 10.1093/brain/awu367. Epub 2014 Dec 24.

8.

Regional brain hypometabolism is unrelated to regional amyloid plaque burden.

Altmann A, Ng B, Landau SM, Jagust WJ, Greicius MD; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2015 Dec;138(Pt 12):3734-46. doi: 10.1093/brain/awv278. Epub 2015 Sep 29.

9.

Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.

Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, O'Neil JP, Gorno-Tempini ML, Miller ZA, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD.

Brain. 2017 Dec 1;140(12):3286-3300. doi: 10.1093/brain/awx243.

10.

In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease.

Kreisl WC, Lyoo CH, McGwier M, Snow J, Jenko KJ, Kimura N, Corona W, Morse CL, Zoghbi SS, Pike VW, McMahon FJ, Turner RS, Innis RB; Biomarkers Consortium PET Radioligand Project Team.

Brain. 2013 Jul;136(Pt 7):2228-38. doi: 10.1093/brain/awt145. Epub 2013 Jun 17.

11.

Relationship of Hippocampal Volume to Amyloid Burden across Diagnostic Stages of Alzheimer's Disease.

Trzepacz PT, Hochstetler H, Yu P, Castelluccio P, Witte MM, Dell'Agnello G, Degenhardt EK; Alzheimer''s Disease Neuroimaging Initiative.

Dement Geriatr Cogn Disord. 2016;41(1-2):68-79. doi: 10.1159/000441351. Epub 2015 Dec 2.

PMID:
26625159
12.

Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.

Edmonds EC, Bangen KJ, Delano-Wood L, Nation DA, Furst AJ, Salmon DP, Bondi MW; Alzheimer’s Disease Neuroimaging Initiative.

J Int Neuropsychol Soc. 2016 Nov;22(10):978-990.

13.

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group.

Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125. Epub 2012 May 23.

PMID:
22628162
14.

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.

Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2010 Nov;133(11):3336-48. doi: 10.1093/brain/awq277. Epub 2010 Oct 8.

15.

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.

Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, Langbaum JB, Ayutyanont N, Roontiva A, Thiyyagura P, Lee W, Mo H, Lopez L, Moreno S, Acosta-Baena N, Giraldo M, Garcia G, Reiman RA, Huentelman MJ, Kosik KS, Tariot PN, Lopera F, Reiman EM.

Lancet Neurol. 2012 Dec;11(12):1057-65. doi: 10.1016/S1474-4422(12)70227-2. Epub 2012 Nov 6.

16.

Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.

Tosun D, Landau S, Aisen PS, Petersen RC, Mintun M, Jagust W, Weiner MW; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2017 May 1;140(5):1499-1512. doi: 10.1093/brain/awx046.

PMID:
28334939
17.

Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC; Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group.

Brain. 2011 Mar;134(Pt 3):798-807. doi: 10.1093/brain/awq383. Epub 2011 Feb 9.

PMID:
21310725
18.

Molecular imaging of dementia.

Mori T, Maeda J, Shimada H, Higuchi M, Shinotoh H, Ueno S, Suhara T.

Psychogeriatrics. 2012 Jun;12(2):106-14. doi: 10.1111/j.1479-8301.2012.00409.x. Review.

19.

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.

Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, Mintun MA, Skovronsky DM, Pontecorvo MJ; AV45-A11 Study Group.

Neurology. 2012 Oct 16;79(16):1636-44. doi: 10.1212/WNL.0b013e3182661f74. Epub 2012 Jul 11.

20.

18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.

Bailly M, Ribeiro MJ, Vercouillie J, Hommet C, Gissot V, Camus V, Guilloteau D.

Clin Nucl Med. 2015 Feb;40(2):e111-6. doi: 10.1097/RLU.0000000000000666.

PMID:
25549345

Supplemental Content

Support Center